Baidu
map

JAMA Oncol :晚期非小细胞肺癌NSCLC免疫治疗中的超进展

2020-08-03 王前前 李明君 肿瘤资讯

研究报道在应用PD-1/PD-L1单药免疫治疗的过程中可能会出现肿瘤侵袭的快速增长,称为超进展(HPD)。然而,迄今为止,尚无HPD共识性的定义。

研究报道在应用PD-1/PD-L1单药免疫治疗的过程中可能会出现肿瘤侵袭的快速增长,称为超进展(HPD)。然而,迄今为止,尚无HPD共识性的定义。Caroline Caramella教授发表在JAMA Oncology的一项研究,旨在评估既往每个HPD定义的准确性,以确定不同HPD定义下晚期非小细胞肺癌(NSCLC)患者HPD的发生率及与免疫检查点抑制剂(ICI)治疗不良结局的相关性,并在所有既往HPD标准的基础上提供一个优化的、一致性较好的HPD定义。

方法

该研究回顾性分析了2012年11月1日至2017年4月5日期间8家法国机构中406例接受PD-1/PD-L1抑制剂治疗的Ⅲ期或Ⅳ期NSCLC患者的数据,大多数患者既往接受过其他治疗。根据RECIST1.1标准定义可测量病灶并进行疗效评价,在开始ICI治疗之前至少有2次CT扫描,在治疗期间至少有1次CT扫描,以评估动态指标。在开始ICI治疗前6周内进行基线CT扫描,用于评估的两次不同的CT之间至少间隔2周的时间,从基线前到基线CT扫描的中位间隔为60天;从基线到后续CT扫描,为62天,最终对2012年11月1日至2019年8月1日的数据进行分析。明确不同定义下HPD的发病率,每种HPD与总生存率之间的关系。在治疗前和治疗过程中计算先前定义中使用的所有动力学指标,如肿瘤生长速率(TGR)或肿瘤生长动力学(TGK)。既往研究中,HPD共有5种不同的标准定义,见表1。

Champiat等(定义A)将HPD定义为治疗期间(exp)TGR较治疗前(ref)至少增加2倍(TGR-exp:TGR-ref≥2),换句话说,免疫治疗过程中肿瘤体积每月增加百分比超过之前的两倍。Kato等(定义B)用3种情况定义了HPD:肿瘤动力学(进展速度>2倍),RECIST百分比(ICIs治疗期间肿瘤负荷增加>50%)和持续治疗时间(治疗失败的时间<2个月)。Saada-Bouzid等(定义C)对HPD的定义依赖于TGK,但TGK并未按肿瘤自然指数增长的假设,使用的是肿瘤直径而不是体积。Singavi等(定义D)采用了定义A以及肿瘤体积增加50%来定义HPD。Ferrara等(定义E)将HPD定义为ICI治疗期间每月的肿瘤体积增加需比治疗前预期的增加50%。

为了研究HPD与生存结果之间的关系,将疾病进展(PD)患者分为HPD和非HPD患者。总生存时间定义为从开始ICI治疗到因任何原因导致患者死亡的时间。治疗失败的时间定义为从开始到因任何原因终止治疗的持续时间,包括毒副反应、疾病进展、患者的选择或死亡。使用Kaplan-Meier方法进行生存分析,并使用对数秩检验进行比较。双侧P<0.05被认为具有统计学意义。

结果

在406例非小细胞肺癌患者中(男性259例;ICI治疗开始时的中位年龄为64),不同定义下HPD的发生率为5.4%~18.5%;不同定义之间的一致性从33.3%~69.3%不等;对于每个定义,HPD与较低的生存率相关[中位总生存率范围,3.4~6.0个月(95%CI,3.7-9.4)];治疗前和治疗中TGR的差异(ΔTGR)与总体生存率差的相关性最大,并且它有最高的能力将HPD患者与未被归类为HPD的进行性疾病患者区分开来。此外,本研究还确定了一个最佳阈值,即ΔTGR>100。

N=1,即根据选择的指标,最多1个患者是HPD;N=2,最多2例患者是HPD,以此类推。当N值比较小时,只有很少的一部分患者可能评估为HPD,这部分患者的生存时间应该较非HPD的PD患者明显更短。当N值较大时,更多的患者被评估为HPD,意味着HPD患者组的总生存时间应该接近于非HPD的患者组。一个好的指标应该在N值较小时两条曲线间隔更大,两条曲线的差距越大越长,该指标越能更好地区分HPD患者和非HPD患者。

TGR-exp/TGR-ref曲线,以及TGK-exp/TGK-ref曲线看起来相似,两条曲线在20例患者之前都显示了一个初始的平台期,但随后中位总生存时间急剧上升,甚至在N足够大时超过了PD患者。ΔTGR曲线在N达到40~50时仍显示初始的平台期,且增长缓慢,证实与总生存的相关性更强。

为了证实三个指标与HPD/非HPD患者预后的相关性,进一步研究了不同指标和不同阈值N的log-rank检验。当N较小时三个指标均达到了P<0.05的统计学差异。但是,当N较大时只有ΔTGR的P值依然<0.05,而另外两个指标P值则在0.05上下波动。

讨论与小结

既往研究显示免疫治疗中HPD的发生率约为4%~29%。造成这种差异的原因可能包括癌症组织学的多样性以及队列研究的规模和来源不同。但是,用于评估HPD的指标也可能是发生率不一致的主要原因。该研究是第一个对迄今为止用于评估HPD所有定义进行详细分析比较的研究。研究结果显示,由于定义本身的缘故,HPD发病率存在高度的不一致性,基于以往HPD定义,HPD发生率差异大,并且这些定义与总生存率的关联不同。指标ΔTGR似乎可能区分出进展迅速、预后差的患者。该研究制定了一个新的标准,将HPD定义为RECIST百分比增大20%,并且ΔTGR>100,未来需要对更大的患者群体进行额外的研究,以确认该定义的准确性和有效性。

该研究也有一定的局限性。首先,HPD最初是在混合肿瘤人群或头颈部鳞状细胞癌患者中进行评估,而该研究仅包括NSCLC患者,有必要对具有不同特征的、更多患者进行研究。其次,一般情况下,因为需要在治疗前进行两次影像学检查,HPD的特征仍难于确定。而且,HPD的所有定义都是基于遵循RECIST 1.1标准进行靶病灶的测量,因此不能解释非靶病灶的明确进展或新发病灶。这种偏倚以及在治疗后进行必要的影像学检查之前死亡的患者被人为的排除,使得无法将死亡与HPD相关联,可能导致对HPD现象的低估。

李明君,副主任医师,博士,郑州大学第一附属医院肿瘤科,副主任医师,博士,JCO肺癌专刊中文版编委,中国医药教育协会肿瘤免疫治疗专业委员会委员,中国老年学和老年医学学会精准医疗分会委员,河南省呼吸与危重症学会肺癌分会青委会 主任委员,河南省抗癌协会肿瘤临床精准诊断与治疗专业委员会青委会副主任委员,河南省呼吸与危重症学会精准医疗分会常务委员,河南省抗癌协会肺癌专业委员会青委会 常务委员,河南省抗癌协会靶向治疗专业委员会青委会常务委员,河南省抗癌协会肿瘤科普专业委员会常务委员。

原始出处:

Baptiste Kas, Hugues Talbot, Roberto Ferrara, et al.Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.JAMA Oncol. 2020 Jun 11;6(7):1039-1046. doi: 10.1001/jamaoncol.2020.1634.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-04-23 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-08-05 ms3000000449926787

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-08-03 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-08-03 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865876, encodeId=e9f618658e6a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 23 00:04:35 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059920, encodeId=ac2720599203f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Dec 10 20:04:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813563, encodeId=e8351813563fa, content=<a href='/topic/show?id=adf8929321e' target=_blank style='color:#2F92EE;'>#超进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92932, encryptionId=adf8929321e, topicName=超进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 25 01:04:35 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806325, encodeId=ab928063258b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:19 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036201, encodeId=42681036201f6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038078, encodeId=80ae10380e88d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039779, encodeId=19761039e791b, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Mon Aug 03 20:04:35 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-08-03 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

2020 POST-ASCO:黄诚教授:纵览肺癌研究热点,了解未来发展方向,探寻更多突破机遇

2020 POST—ASCO会议信息交流会肺癌专场在蓉顺利举行,会议旨在向国内肿瘤学者传递2020美国临床肿瘤学会(ASCO)年会关于肺癌的最新研究。

2020 WCGIC 晚期结直肠癌研究解读

由欧洲肿瘤内科学会主办的世界胃肠道肿瘤大会(WCGIC)在线上举行。肠癌专场公布3个LBA研究,6个口头报告,20个短口头报告。部分探索性研究仍值一读,或许能为广大临床工作者开展晚期肠癌研究提供参考。

Laryngoscope:lgE的早期反应能够预测舌下免疫治疗的满意度

最近,有研究人员在过敏性鼻炎患者中进行了一个回顾性的队列研究,调查了基线时间点和屋尘螨舌下免疫治疗(SLIT)早期响应期间的预测参数。

Allergy Asthma Immunol Res:屋尘螨免疫治疗对鼻过敏原挑战的上、下呼吸道嗜酸性炎症响应影响

是否过敏原特异性免疫治疗(AIT)能够减弱过敏原接触引发的气道炎症响应仍旧未知。

Brit J Cancer:抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响

放疗能够增强先天性和适应性抗肿瘤免疫。然而,并不清楚该效应能否通过免疫治疗和放疗联用治疗前列腺癌来增强。最近,有研究人员调查了预临床前列腺癌模型对放疗的肿瘤免疫微环境响应情况,并检测了是否放疗诱导的肿

Nat Immunol :癌症免疫治疗新靶点——NRP1

虽然抗PD-1/L1等免疫检查点阻断疗法已经彻底改变了癌症治疗,但只有一小部分癌症患者表现出持久的临床反应。。因此,人们对识别先前存在和获得性免疫耐药机制以及开发新的预防复发的治疗方法非常感兴趣。

Baidu
map
Baidu
map
Baidu
map